Tailored WJ-MSC & exosome protocols for Crohn's and ulcerative colitis
Stem cell therapy for inflammatory bowel disease in Istanbul, Turkey
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat evaluates your ulcerative colitis or Crohn's disease profile to design an individualized Wharton's jelly MSC and exosome protocol.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Understanding the condition
Understanding the condition and our regenerative approach
Inflammatory bowel disease (IBD) — encompassing both ulcerative colitis and Crohn's disease — is characterized by chronic, relapsing immune activation within the digestive tract that strips away the protective intestinal lining and disrupts daily life. When mucosal immune tolerance breaks down, waves of inflammatory cells damage the colonic or small-intestinal epithelium, causing abdominal pain, frequent urgency, mucosal bleeding, nutrient depletion, and a pervasive inflammatory fatigue that makes everyday routines feel overwhelming.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes offer a comprehensive biological approach designed to calm this immune overactivity and help repair damaged gut tissues. Acting through systemic immunomodulation, WJ-MSCs downregulate pro-inflammatory cytokines including TNF-alpha, IL-6, IL-1beta, and the IL-17/IL-23 axis, convert tissue-destructive M1 macrophages into pro-healing M2 macrophages, and expand FoxP3+ regulatory T-cells (Tregs) that restore mucosal immune balance. At the same time, nanoscale WJ-MSC exosomes deliver regenerative microRNAs, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) directly to intestinal crypt stem cells and goblet cells — helping regenerate the mucin layer, seal epithelial tight junctions, and nourish healthy microvascular perfusion across the bowel wall.
At our regenerative medicine clinic in Istanbul, Uzm. Dr. Cihan Bolat and our medical team carefully evaluate your exact diagnosis (ulcerative colitis vs. Crohn's disease), colonoscopy and biopsy reports, fecal calprotectin, CRP, and current medications to design an individualized protocol. Coordinated seamlessly alongside your home gastroenterologist's care, our biological program aims to support mucosal recovery, calmer digestion, and renewed physical stamina.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
Key biological processes and therapeutic targets
In both ulcerative colitis and Crohn's disease, persistent gut inflammation stems from an imbalance between aggressive effector immune cells and regulatory repair mechanisms. Regenerative therapy targets these shared immunologic cascades and delivers trophic factors to rebuild the epithelial barrier.
What our protocol aims to support
- Rebalancing gut-associated immune signaling: Supporting regulatory T-cell (Treg) pathways and calming excessive TNF-alpha, IL-6, and IL-17/23 inflammatory signaling across the digestive tract.
- Nourishing mucosal & epithelial recovery: Providing paracrine trophic factors and exosomal microRNAs that support epithelial crypt turnover, goblet-cell mucin health, and intestinal barrier function.
- Supporting systemic vitality & symptom stability: Helping reduce the systemic inflammatory burden that contributes to chronic fatigue, digestive urgency, anemia, and reduced quality of life.
- Seamless coordination with your IBD specialist: All regenerative protocols in Istanbul are planned alongside your ongoing 5-ASA, immunomodulator, or biologic therapy managed by your home gastroenterologist.
- 01
Mucosal & transmural immune dysregulation
Whether confined to the colonic mucosa and submucosa in ulcerative colitis or extending through the full bowel wall in Crohn's disease, loss of regulatory T-cell (Treg) control allows Th1 and Th17 lymphocytes to attack healthy digestive tissue. This unchecked lymphocyte activity drives chronic cryptitis, ulceration, and mucosal friability. Wharton's jelly MSCs release immunomodulatory mediators (IDO, PGE2, TGF-beta, and IL-10) that suppress aggressive T-cell proliferation and promote Treg expansion. Restoring this regulatory balance helps quiet the autoimmune trigger behind recurrent IBD flares.
- 02
Pro-inflammatory cytokine cascades (TNF-alpha, IL-6, IL-17/23)
Excessive production of TNF-alpha, IL-6, and IL-17/23 recruits waves of neutrophils into the intestinal crypts, forming crypt abscesses, triggering mucosal bleeding, and generating profound systemic fatigue. These cytokines also disrupt hepatic iron handling and drain daily physical energy. WJ-MSCs and their exosomes deliver anti-inflammatory microRNAs that inhibit NF-kappaB and STAT3 signaling pathways inside activated immune cells. By dampening these cytokine cascades, our biological protocol helps reduce mucosal congestion, digestive urgency, and systemic exhaustion.
- 03
Macrophage M1 polarization & matrix degradation
In inflamed IBD tissue, resident and recruited macrophages remain skewed toward a destructive M1 phenotype, releasing reactive oxygen species and matrix-degrading enzymes that prevent ulcers from closing and promote submucosal fibrosis. Without a transition to the reparative M2 macrophage state, tissue remodeling stalls. Paracrine signals and exosomal cargo from WJ-MSCs actively reprogram M1 macrophages into M2 healing macrophages that clear cellular debris and secrete pro-resolving factors. This macrophage shift supports smoother, more elastic tissue repair across the colonic and intestinal wall.
- 04
Intestinal epithelial barrier & mucin-layer breakdown
A healthy gut lining depends on mucin-producing goblet cells and tight-junction complexes that keep luminal bacteria separated from the mucosal immune system. In IBD, goblet cell depletion and epithelial apoptosis create a 'leaky' barrier that continually re-exposes immune cells to microbial antigens. WJ-MSC exosomes transfer trophic growth factors (EGF, HGF, IGF-1) and protective RNAs directly to intestinal epithelial progenitors, supporting crypt regeneration and tight-junction protein synthesis. Strengthening this physical and biochemical barrier is vital for calmer digestion and long-term mucosal resilience.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Calming the Gut Immune Cascade
Chronic intestinal inflammation in IBD is sustained when effector T-cells and innate immune cells continuously release TNF-alpha, IL-6, and IL-17/23 while regulatory T-cell (Treg) braking falters. This ongoing immune assault erodes the mucus shield and damages the epithelial crypts responsible for renewing the gut lining every few days. Regenerative medicine is investigated because targeting both immune dysregulation and epithelial stem-cell exhaustion is essential for durable tissue recovery. By quieting inflammatory signaling at its root, biological therapy helps restore a microenvironment conducive to mucosal healing.
Dual Cellular & Exosomal Tissue Repair
Wharton's jelly-derived MSCs (WJ-MSCs) provide potent, immunoprivileged paracrine signaling that shifts intestinal macrophages from pro-inflammatory M1 states toward reparative M2 states and boosts anti-inflammatory IL-10 production. Complementing the cells, WJ-MSC-derived exosomes circulate systemically as nanoscale lipid vesicles packed with regulatory microRNAs, HGF, VEGF, and trophic proteins. These vesicles penetrate deep into the colonic and small-intestinal mucosa to protect Lgr5+ crypt stem cells from apoptosis, stimulate goblet-cell mucin restoration, and rebuild tight-junction proteins. Together, they address both systemic immune activation and local barrier breakdown.
Phenotype-Matched Istanbul Protocol
Because ulcerative colitis (continuous colonic mucosal inflammation) and Crohn's disease (patchy transmural inflammation) differ in anatomy and clinical behavior, our medical team never uses a one-size-fits-all template. Uzm. Dr. Cihan Bolat reviews your endoscopic extent, pathology, fecal calprotectin, hemoglobin, albumin, and current biologic or 5-ASA regimen before designing your treatment plan. We customize the exact WJ-MSC cell count, exosome dosage, and delivery routes to complement your ongoing specialist care safely. Structured 1, 3, and 6-month follow-ups then track your inflammatory markers and daily digestive stability.
Our treatment approach & administration routes
How our proposed Wharton's jelly MSC and exosome protocols work
- 01
Intravenous Wharton's Jelly MSC (WJ-MSC) Infusion
Intravenous administration introduces high-potency, GMP-certified Wharton's jelly MSCs into the systemic circulation to regulate both circulating immune cells and gut-homing lymphocytes. Through paracrine secretion of IL-10, PGE2, and trophic cytokines, WJ-MSCs help quiet overactive Th1/Th17 signaling, shift intestinal macrophages from destructive M1 to reparative M2 states, and expand regulatory T-cells. This systemic immunomodulation helps calm mucosal congestion, reduce inflammatory bleeding, and support healthy microvascular blood flow across the colon and small intestine. Every infusion is performed in our supervised clinical setting with full viability documentation.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 02
Intravenous WJ-MSC-Derived Exosome Administration
WJ-MSC-derived exosomes are nanoscale extracellular vesicles packed with anti-inflammatory microRNAs, growth factors (HGF, VEGF, EGF), and signaling proteins that circulate freely to the intestinal mucosa. Once internalized by epithelial crypt cells and lamina propria immune cells, these exosomes help downregulate NF-kappaB inflammatory pathways, protect epithelial progenitors from oxidative stress, and stimulate tight-junction and mucin-layer repair. Administered alongside WJ-MSCs, exosomes provide immediate vesicular signaling while the stem cells establish broader immunomodulatory support. We note transparently that whether combined MSC and exosome therapy outperforms single-modality treatment remains under clinical investigation.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 03
Intramuscular Administration (When Included in Your Protocol)
In selected IBD protocols, intramuscular delivery is included to establish a localized muscular depot for gradual, sustained paracrine factor release. Because intravenously infused MSCs undergo initial first-pass trapping in the lungs, placing a portion of biologics within well-perfused muscle tissue allows prolonged survival and steady secretion of anti-inflammatory cytokines and exosomes into the bloodstream. This depot effect aims to extend trophic and immunomodulatory support for the gut lining over a longer post-treatment window. We distinguish this biological depot rationale from established clinical trial proof of pharmacokinetic superiority.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
What we aim to achieve
Therapeutic objectives and functional outcomes we track
Before treatment in Istanbul, our physicians establish your clinical baseline and define realistic biological and functional objectives to track during follow-up.
- 01
Intestinal Barrier & Biomarker Recovery
By quieting mucosal cytokine storms and supporting crypt regeneration, our protocol aims to help lower fecal calprotectin, CRP, and ESR levels while supporting healthier endoscopic mucosa over time.
- 02
Calmer Digestion & Reduced Urgency
Repairing epithelial tight junctions and soothing colonic or small-bowel inflammation helps decrease daily bowel frequency, tenesmus, abdominal cramping, and mucosal irritation.
- 03
Hemoglobin, Iron & Nutritional Resilience
As mucosal friability and micro-bleeding subside and absorptive surface health improves, patients are better able to maintain healthy iron stores, hemoglobin, albumin, and body weight.
- 04
Systemic Energy & Daily Freedom
Reducing the chronic systemic inflammatory load helps alleviate deep IBD-related fatigue and joint aches, restoring confidence for work, social outings, and travel.
How treatment is personalized
How our medical team evaluates your records and designs your protocol
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat evaluates your ulcerative colitis or Crohn's disease profile to design an individualized Wharton's jelly MSC and exosome protocol.
Medical history & reports we request
- Confirmed diagnosis of ulcerative colitis or Crohn's disease and disease duration
- Most recent colonoscopy, pathology, and cross-sectional imaging reports
- Recent laboratory panel including fecal calprotectin, CRP, CBC, and albumin
- Complete list of current and past IBD biologics, small molecules, or steroids
- Overview of daily symptoms, flare frequency, and extra-intestinal manifestations
Clinical suitability & protocol checks
- We coordinate your Istanbul visit so that your regular biologic infusion or oral IBD medication schedule remains uninterrupted.
- Acute severe colitis, significant gastrointestinal bleeding, or high fever requires immediate stabilization with your local medical team prior to travel.
- Following your treatment in Istanbul, our medical team conducts structured follow-up reviews at 1, 3, and 6 months to track your biomarkers and symptom progress.
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
- 01
Contact us & share your medical reports
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
- 02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
- 03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
- 04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Transparent Istanbul pricing tailored to your protocol
After our medical team evaluates your records, we provide a written proposal explaining the recommended Wharton's jelly MSC and exosome preparations, administration routes, intended objectives, stay timeline, and itemized costs.
For 2026 planning context, targeted exosome and local orthopedic protocols typically range from $3,500–$6,500, while comprehensive Wharton's jelly MSC and exosome programs range from $7,000–$18,000. Your exact cost is confirmed after your medical evaluation.
- We coordinate your Istanbul visit so that your regular biologic infusion or oral IBD medication schedule remains uninterrupted.
- Acute severe colitis, significant gastrointestinal bleeding, or high fever requires immediate stabilization with your local medical team prior to travel.
- Following your treatment in Istanbul, our medical team conducts structured follow-up reviews at 1, 3, and 6 months to track your biomarkers and symptom progress.
What your written treatment proposal explains
- 01
Which Wharton's jelly MSC, exosome, or combined protocol is proposed for your condition?
- 02
Which administration routes are recommended and how do they work biologically?
- 03
What are the intended therapeutic objectives and expected stay length in Istanbul?
- 04
What is the itemized cost and how does 1, 3, and 6-month follow-up work after treatment?
Evidence & important considerations
Published clinical research and important considerations
Below is a summary of published human studies, investigated mechanisms, and important limitations relevant to regenerative medicine for this condition.
01 Clinical guidelines and translational research in ulcerative colitis and IBD
Open study- Product
- Wharton's jelly and umbilical cord mesenchymal stromal cells and exosomes
- Route
- Intravenous systemic immunomodulatory administration
- Study design
- Evidence-based clinical guideline and translational MSC immunomodulation studies
- Finding
- Translational and early clinical studies examine systemic MSC and exosome infusions for immune regulation and mucosal support alongside established IBD therapies.
- Limitation
- Systemic cell and exosome infusions remain supportive immunomodulatory options and do not replace routine endoscopic surveillance or prescribed IBD maintenance medications.
02 Allogeneic MSC clinical trial experience in complex Crohn's disease
Open study- Product
- Expanded allogeneic mesenchymal stromal cells
- Route
- Targeted clinical protocol
- Study design
- Phase 3 randomized controlled clinical research program
- Finding
- Demonstrated the safety profile of allogeneic MSCs in IBD populations while highlighting that clinical response varies by disease subtype and administration strategy.
- Limitation
- Confirmatory fistula trial endpoints did not surpass placebo, underscoring the need for individualized patient selection and realistic therapeutic goals.
Scientific references
Clinical studies and scientific references
- ECCO guidelines on medical management of ulcerative colitisEuropean Crohn's and Colitis Organisation · Clinical guideline
- ECCO clinical guidelines on Crohn's disease managementEuropean Crohn's and Colitis Organisation · Clinical guideline
- EMA update on allogeneic mesenchymal stromal cell clinical dataEuropean Medicines Agency · Regulatory source
FAQ
Frequently asked questions about this treatment
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.